

Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy Subjects

Paola Patrignani, ... , Paola Filabozzi, Carlo Patrono

J Clin Invest. 1982;69(6):1366-1372. <https://doi.org/10.1172/JCI110576>.

Research Article

Acetylation of platelet cyclooxygenase by oral aspirin is dose dependent and cumulative with repeated administration. However, no single dose of aspirin has been found to be completely selective of platelet thromboxane (TX) synthesis inhibition in man. We determined the dose dependence, cumulative nature and selectivity of aspirin effects on platelet TXB₂ and renal prostaglandin (PG) and prostacyclin (PGI₂) production. We measured, by radioimmunoassay, serum TXB₂ levels after whole blood clotting and urinary excretion of PGE₂, PGF_{2α}, and 6-keto-PGF_{1α}, before and after single or repeated oral aspirin doses given to 46 healthy subjects. Single doses of 6-100 mg aspirin resulted in a linear ($r = 0.92$, $P < 0.01$) inhibition of platelet TXB₂ production, ranging from 12 to 95% after 24 h. A daily dose of 0.45 mg/kg given for 7 d produced a cumulative and virtually complete inhibition of platelet TXB₂ production, without significantly reducing the urinary excretion of PGE₂, PGF_{2α}, and 6-keto-PGF_{1α} in both healthy men and women. The platelet inhibitory effect of this regimen was maintained unaltered throughout 1 mo of therapy, with no evidence of cumulative inhibition of renal PG-synthesis. Moreover, furosemide-induced renal PGI₂ synthesis and renin release were unaffected by chronic low-dose aspirin. Following cessation of aspirin therapy, platelet TXB₂ production returned toward control values at a similar rate as after a single higher dose.

We [...]

Find the latest version:

<https://jci.me/110576/pdf>



Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy Subjects

PAOLA PATRIGNANI, PAOLA FILABOZZI, and CARLO PATRONO, *Department of Pharmacology, Catholic University School of Medicine, 00168 Rome, Italy*

ABSTRACT Acetylation of platelet cyclooxygenase by oral aspirin is dose dependent and cumulative with repeated administration. However, no single dose of aspirin has been found to be completely selective of platelet thromboxane (TX) synthesis inhibition in man. We determined the dose dependence, cumulative nature and selectivity of aspirin effects on platelet TXB₂ and renal prostaglandin (PG) and prostacyclin (PGI₂) production. We measured, by radioimmunoassay, serum TXB₂ levels after whole blood clotting and urinary excretion of PGE₂, PGF_{2α}, and 6-keto-PGF_{1α}, before and after single or repeated oral aspirin doses given to 46 healthy subjects. Single doses of 6–100 mg aspirin resulted in a linear ($r = 0.92$, $P < 0.01$) inhibition of platelet TXB₂ production, ranging from 12 to 95% after 24 h. A daily dose of 0.45 mg/kg given for 7 d produced a cumulative and virtually complete inhibition of platelet TXB₂ production, without significantly reducing the urinary excretion of PGE₂, PGF_{2α}, and 6-keto-PGF_{1α} in both healthy men and women. The platelet inhibitory effect of this regimen was maintained unaltered throughout 1 mo of therapy, with no evidence of cumulative inhibition of renal PG-synthesis. Moreover, furosemide-induced renal PGI₂ synthesis and renin release were unaffected by chronic low-dose aspirin. Following cessation of aspirin therapy, platelet TXB₂ production returned toward control values at a similar rate as after a single higher dose.

We conclude that in healthy subjects: (a) aspirin causes a dose-dependent inhibition of platelet TXA₂ production, with no obvious sex-related difference; (b) the inhibitory effect of daily low-dose aspirin is cumulative on platelet TXA₂ but not on renal PG-synthesis; (c) during chronic low-dose aspirin therapy, renal PGI₂-producing cells are readily activable by furosemide at a time of virtually complete suppression of platelet cyclooxygenase activity.

This work was presented in part at the Annual Meeting of the American Federation for Clinical Research, 27 April 1981, San Francisco, CA. (1).

Received for publication 21 July 1981 and in revised form 5 February 1982.

INTRODUCTION

Aspirin acetylates the active site of cyclooxygenase (2), the enzyme converting arachidonic acid into the prostaglandin (PG)¹ cyclic endoperoxides, thereby reducing their further transformations into stable and unstable biologically active compounds, i.e. PG, prostacyclin (PGI₂) and thromboxane (TX)A₂. Reduced formation of these metabolites in different target tissues can probably account for the wide variety of pharmacologic effects of the drug, which form the basis of its therapeutic use and its toxicity (3). Thus, the use of aspirin as an antithrombotic agent is predicated on the assumption that blockade of the cyclooxygenase pathway of platelet arachidonic acid metabolism favorably affects pathological thrombosis by virtue of a reduced TXA₂ formation. However, doses of the drug in the range of 300–1,500 mg also cause a variable inhibition of the same pathway in vascular tissue (4), gastric mucosa (5), and renal tissue (6). The functional consequences of these extra platelets effects of aspirin are currently held responsible for reduced antithrombotic activity, increased incidence of gastric erosions and reduced renal function in some patients (3). Numerous attempts have been made in recent years in order to find an ideal dose of aspirin that would inhibit cyclooxygenase in platelets but not in other tissues, particularly in the vessel wall. However, most human studies, based on single-dose experiments, have failed to demonstrate the existence of such a "therapeutic window."

The aims of the present investigation were: (a) to characterize the dose dependence of aspirin effect on platelet TXA₂ formation in healthy subjects, in order to define low-dose vs. high-dose for this particular effect of the drug; (b) to determine whether cumulative inhibition of platelet TXA₂ formation by daily administration of low-dose aspirin would also affect the cy-

¹ *Abbreviations used in this paper:* PG, prostaglandin (used variously according to the identification of a given prostaglandin, i.e. PGE₂ or PGI₂); RIA, radioimmunoassay; TX, thromboxane.

cloxygenase pathway of renal arachidonic acid metabolism, i.e., a well recognized target of aspirin toxicity; (c) to measure the long-term effects of this potential therapeutic regimen on platelet and renal PG formation and to characterize the recovery pattern of cyclooxygenase activity upon discontinuing the drug.

The results of this study demonstrate that a daily dose of aspirin as low as 0.45 mg/kg causes a cumulative inhibition of platelet TXA₂ formation without interfering with renal PG synthesis in healthy subjects.

METHODS

Subjects. A total of 46 healthy volunteers were studied (7 male, M; 39 female, F; ages 18–37 yr). They were students, nurses and graduates of the Catholic University Medical School, who gave their informed consent to participate in this study. A careful interview was entertained with each of them in order to exclude the intake of nonsteroidal antiinflammatory drugs during the 2 wk preceding each phase of the study. Several subjects were studied repeatedly.

Single-dose study. To establish the dose-response relation for the inhibitory effect of aspirin on platelet TXA₂ production, 4–14 volunteers were randomly allocated to different treatment groups i.e., 6, 12, 25, 50, and 100 mg. Aspirin capsules were prepared by directly weighing acetylsalicylic acid (Bayer AG, Leverkusen, West Germany). 3–5-ml peripheral blood samples were drawn by venipuncture, in the fasting state, before, and 24 h after oral aspirin administration. Platelet TXA₂ production during whole blood clotting was studied as described below.

Multiple-dose studies. In nine subjects (4 M, age 36.3±0.5 yr, weight 74.8±10.2 kg; 5 F, age 27.4±4.3 yr, weight 50.8±7.2 kg; mean±SD) the effects of daily 20–40 mg doses of the drug were investigated on platelet TXA₂ formation and urinary PGE₂, PGF_{2α}, and 6-keto-PGF_{1α} (the stable breakdown product of PGI₂) excretion. For this purpose, blood and urine samples were collected daily during 1 control wk and during 1 wk of aspirin therapy (0.45±0.03 mg/kg per d; mean±SD). 1 mo after completion of the study, two female subjects underwent 1 wk of aspirin treatment at a dose of 0.5 and 1.0 g daily (10.2 and 17.5 mg/kg per d, respectively), and blood and urine samples were collected similarly.

In order to demonstrate long-term maintenance and selectivity of the cumulative inhibitory effect of low-dose aspirin, three of the same subjects (1 F, 2 M; age 33±6.7 yr) underwent aspirin treatment (0.45±0.02 mg/kg per d) for 1 mo. Blood samples were drawn three times weekly, the week before starting treatment, the 2nd, 3rd, and 4th wk of treatment, and the 2nd wk after discontinuing the drug; they were taken daily during the 1st wk of treatment and the 1st wk after discontinuing aspirin. Urine samples were collected three times weekly throughout the study. In all multiple-dose studies, aspirin was taken shortly before midnight (immediately after voiding) and urine collected from midnight to 8 a.m. A 100-ml aliquot of the 8-h collection was frozen immediately after voided and kept at -20°C until extracted. The rationale for 8-h rather than 24-h urine collections was: (a) greater reproducibility of urinary PG excretion measured in the same subjects on successive days, because of uniformly standardized conditions; (b) greater chances of detecting a moderate reversible inhibition of renal PG synthesis induced by chronic aspirin intake. Venous blood samples (3 ml) were drawn at 10 a.m., 2 h after a light

breakfast. Platelet TXA₂ production in response to endogenous thrombin was studied by letting triplicate 1-ml aliquots of whole blood to clot at 37°C for 60 min, as previously described (7). The separated sera were frozen and kept at -20°C until assayed. In addition, the acute effects of furosemide, which is known to induce an immediate overall activation of renal PG synthesis and renin release (8, 9), were investigated under control conditions and again during the 3rd and 4th wk of aspirin treatment. For this purpose, a 4-h control sample before and three consecutive urine samples after an intravenous injection of furosemide (Lasix, Hoechst AG, Frankfurt, West Germany: 0.64±0.09 mg/kg) were collected and immediately frozen. Samples of peripheral venous blood (10 ml) were drawn into iced tubes containing EDTA, before and 15 and 180 min after furosemide. The separated plasma was frozen immediately and kept at -20°C until assayed for renin activity.

Analyses. Serum TXB₂ (the stable breakdown product of TXA₂) concentrations were measured by a previously described radioimmunoassay (RIA) technique (10). Unextracted serum samples were diluted in the standard diluent of the assay (0.02M PO₄ buffer, pH 7.4) and assayed in a volume of 1.5 ml at a final dilution of 1:500–1:15,000. The assay uses 5,000 dpm of [³H]TXB₂ (New England Nuclear, Boston, MA: 150 Ci/mM) and a rabbit anti-TXB₂ serum diluted 1:1,000,000. The least detectable concentration that can be measured with 95% confidence (i.e., 2 SD at zero) is 2 pg of TXB₂/ml of incubation mixture. Therefore, the detection limit of the assay was 1 ng of TXB₂/ml of serum, i.e., ~0.5% of the serum TXB₂ concentration measured in healthy subjects (7). Validation of TXB₂ measurements was obtained by three independent criteria: (a) dilution and recovery studies; (b) characterization of the chromatographic pattern of distribution of extracted TXB₂-like immunoreactivity on thin-layer chromatography, as described in detail elsewhere (7); (c) comparison with other anti-TXB₂ sera. Two additional anti-TXB₂ sera were used at final dilutions of 1:200,000 and 1:100,000, respectively. The IC₅₀ values (concentrations of unlabeled TXB₂ required to displace 50% of bound [³H]TXB₂) of the three antisera used were: 17, 14, and 15 pg/ml. The cross-reactivities of some relevant arachidonic acid metabolites with the two additional anti-TXB₂ sera are described in Table I. Urinary PGE₂, PGF_{2α}, and 6-keto-PGF_{1α}, which reflect, within limits, the renal synthesis of PGE₂, PGF_{2α} (11), and PGI₂ (9), respectively, were measured by RIA techniques after extraction and silicic acid column chromatography (12, 9). Validation of RIA measurements was obtained by several independent criteria, i.e., comparison among multiple anti-PG sera; characterization of the thin-layer chromatography pattern of distribution of the extracted PG-like immunoreactivity; comparison with gas chromatography/mass spectrometry determinations. These techniques are described in detail elsewhere (12, 9).

Plasma renin activity was measured by RIA of angiotensin I, as described by Haber et al. (13), using a commercially available kit (Sorin Biomedica, Saluggia, Italy).

Results were subjected to analysis of variance and Student's *t* test.

RESULTS

In 33 healthy subjects, who were studied before and 24 h after single aspirin administrations, serum TXB₂ concentrations averaged 228±87 ng/ml (mean±SD) in the control state. The lowest single dose of aspirin causing a statistically significant reduction (31±15%,

TABLE I
Immunological Specificity of Antisera Directed against TXB₂

Substance measured	AS	AS
	2	3
Relative cross-reaction		
%		
TXB ₂	100	100
2,3-dinor-TXB ₂	1.3	2.0
PGF _{2α}	0.3	0.5
PGD ₂	0.03	0.05
2,3-dinor-6-keto-PGF _{1α}	0.01	0.03
PGE ₂	0.005	0.003
6-keto-PGF _{1α}	0.002	0.004
13,14-DH-6,15-DK-PGF _{1α}	<0.001	<0.002
6-keto-PGE ₁	<0.001	<0.002
LTC ₄	<0.001	<0.002
LTD ₄	<0.001	<0.002

AS, antisera.
LT, leukotriene.

$P < 0.01$) of serum TXB₂ concentrations was 12 mg. As shown in Fig. 1, oral aspirin administration caused a dose-dependent inhibition of platelet TXB₂ production, achieving virtually complete suppression of cyclooxygenase activity at 100 mg (95±4% inhibition). A statistically significant correlation was found between the aspirin dose and percentage reduction of serum TXB₂ concentrations ($r = 0.92$, $P < 0.01$, $n = 33$).

Five control sera and five sera obtained 24 h after aspirin were subjected to RIA using three different anti-TXB₂ sera. A statistically significant correlation was found among the three sets of data: $r = 0.999$, 0.961 , and 0.963 , $P < 0.001$. The mean coefficient of variation for the whole series was 13.1%, a figure not




FIGURE 1 Inhibition of platelet TXB₂ production by oral aspirin. TXB₂ production during whole blood clotting was measured before and 24 h after aspirin ingestion. The results are expressed as percent inhibition, each subject serving as his or her own control. Mean values±1 SD are plotted. Numbers in parentheses indicate the number of subjects for each dose of aspirin.

significantly different from the 11.1% value found in a previous study when multiple 1-ml aliquots of the same blood samples were analyzed with the same antiserum (7).

The base-line values of serum TXB₂, urinary PGE₂, PGF_{2α}, and 6-keto-PGF_{1α} excretion of five healthy women and four healthy men, measured daily during a 7-d control period, are reported in Table II. No statistically significant differences were found between male and female values of each of the four parameters. The intrasubject variability, measured during 7 consecutive d, averaged 14±5% (mean±SD, $n = 9$) for serum TXB₂, and 30±10, 19±5, 18±8% for urinary PGE₂, PGF_{2α}, and 6-keto-PGF_{1α} excretion. Men had a significantly higher coefficient of variation for urinary PGE₂ excretion as compared to women: 37±6 vs. 24±9% ($P < 0.025$). No statistically significant differences were found for the other compounds measured. Urine volume during the 8-h collection period (7.85±0.9 h) averaged 31±15 ml/h (mean±SD, $n = 63$), with no statistically significant difference between men and women. The excretion of PGE₂, PGF_{2α}, and 6-keto-PGF_{1α} did not correlate with urine volume to any significant extent ($r = 0.24$, 0.26 , and 0.15 , respectively).

As shown in Fig. 2, a daily aspirin dose of 0.45 mg/kg caused a statistically significant ($P < 0.005$) reduction of serum TXB₂ concentrations, which averaged 36% after the first dose, 70% after the second dose, 87% after the third dose, and 95% after the fourth dose. Under the same circumstances, the urinary excretion of renal PG was not affected to any statistically significant extent, in either female or male subjects. The urinary excretion rates of PGE₂, PGF_{2α}, and 6-keto-PGF_{1α} averaged 10.8±4.9 ng/h (mean±SD, $n = 63$), 23.9±9.0 and 4.7±2.6 during the 7-d aspirin period as compared to 10.7±4.7, 20.7±4.8, and 4.7±1.9, respectively, during the 7-d control period. Aspirin did not affect urine volume, which averaged 32±13 ml/h during a 7-d period. Although the urinary excretion of 6-keto-PGF_{1α} measured during the last 3 d of aspirin

TABLE II
Mean (±SD) Base-line Values of Serum TXB₂ Concentration and Urinary (U) PGE₂, PGF_{2α}, and 6-Keto-PGF_{1α} Excretion, Measured Daily during a 7-d Period in Nine Healthy Subjects (4 M, 5 F)

Compound measured	Men	Women	P
	$n = 28$	$n = 35$	
Serum TXB ₂ , ng/ml	321±55	299±128	NS
U-PGE ₂ , ng/h	11.6±4.5	10.2±4.9	NS
U-PGF _{2α} , ng/h	20.4±5.4	21.0±4.6	NS
U-6-Keto-PGF _{1α} , ng/h	4.8±2.4	4.6±1.6	NS




FIGURE 2 Effect of daily low-dose (0.45 mg/kg) aspirin on platelet TXB₂ and renal PG-synthesis. Serum TXB₂ concentrations and urinary excretion of 6-keto-PGF_{1α}, PGE₂, and PGF_{2α} were measured in nine healthy subjects during 7 consecutive control d and 1 wk of aspirin therapy. Mean values±SEM are plotted. The arrows indicate daily aspirin intake.

treatment was ~20% lower than during the first 4 d, this difference did not reach statistical significance. In two of the same subjects who underwent 1 wk of aspirin treatment at doses of 0.5 and 1 g daily, the urinary excretion of 6-keto-PGF_{1α} (2.8 ± 0.6 and 1.9 ± 0.4), PGE₂ (6.2 ± 1.4 and 4.0 ± 0.9), and PGF_{2α} (12.6 ± 2.2 and 8.5 ± 1.5) was significantly ($P < 0.01$) reduced by ~40 and 60%, respectively, with no evidence of cumulative inhibition as a function of time. The long-term effects of this therapeutic regimen were reassessed in three of the same subjects in order to verify maintenance of the platelet inhibitory effect and to ascertain whether appreciable changes of renal PG synthesis might become apparent on a more chronic basis. As shown in Fig. 3, serum TXB₂ showed cumulative in-




FIGURE 3 Long-term effects of low-dose (0.45 mg/kg per d) aspirin on platelet TXB₂ and renal PGI₂ synthesis. Serum TXB₂ concentrations and urinary excretion of 6-keto-PGF_{1α} were measured in three healthy subjects before, during, and after aspirin therapy. Mean values±SEM are plotted. The arrows indicate duration of daily aspirin therapy.

hibition with a pattern substantially similar to the previous study. Greater than 95% inhibition of platelet TXB₂ production was maintained throughout the whole treatment period. Upon discontinuing aspirin, platelet TXB₂ production returned with a time course similar to that described following a single 100-mg dose (7) and consistent with platelet turnover and reappearance of unacetylated platelet cyclooxygenase (14). Platelet life-span calculated by linear regression analysis, assuming a 2-d lag period before enzyme recovery (14), averaged 9.2 ± 1.6 d (mean±SD). The urinary excretion of 6-keto-PGF_{1α} measured during the same period ranged between 82 and 108% of control values, with no statistically significant changes throughout the whole month. The urinary excretion of PGE₂ and PGF_{2α} followed a substantially similar pattern (not shown). The excretion rates of 6-keto-PGF_{1α}, PGE₂, and PGF_{2α} averaged 4.0 ± 2.0 ng/h (mean±SD, $n = 36$), 13.5 ± 6.1 and 34.1 ± 16.4 during the 31-d aspirin period as compared with 3.9 ± 1.9 (mean±SD, $n = 27$), 14.3 ± 6.3 and 33.1 ± 15.6 , respectively, during the 21-d control period.

The fate of plasma renin activity and urinary 6-keto-PGF_{1α} following the administration of a pharmacologic stimulus known to stimulate renin release through increased renal PGI₂ synthesis (9) was investigated by infusing furosemide into the same subjects, under control conditions and during the 3rd and 4th wk of aspirin treatment. As shown in Fig. 4, furosemide caused a statistically significant increase of urinary 6-keto-PGF_{1α}, with a substantially similar pattern under control and chronic aspirin treatment. Under all circumstances, the excretion rate of 6-keto-PGF_{1α} increased approximately fourfold over basal levels, remained significantly elevated over a period of 60 min and declined thereafter. Plasma renin activity rose signifi-




FIGURE 4 Furosemide infusion under control conditions and during low-dose (0.45 mg/kg per d) aspirin therapy. The time course of urinary 6-keto-PGF_{1α} excretion rates following the infusion of furosemide (0.64 mg/kg, i.v.) was measured in three healthy subjects before (the lower panel) and during the 3rd (the middle panel) and 4th (the upper panel) wk of aspirin therapy. Mean values ± SEM are plotted. The level of significance of the difference between values obtained before and after furosemide was determined by the paired *t* test. **P* < 0.01, ***P* < 0.005.

cantly (*P* < 0.005) after 15 min, and remained significantly elevated at 180 min, under control conditions (236 ± 67%, mean ± SD, *n* = 3) as well as during chronic aspirin treatment (237 ± 64%, mean ± SD, *n* = 9) (not shown).

DISCUSSION

Among numerous substances inhibiting platelet function, aspirin is unique in causing an irreversible defect persisting for the life-span of the exposed platelets. The mechanism underlying this long-lasting defect involves acetylation by aspirin of the active site of platelet cyclooxygenase, which results in irreversible inactivation of the enzyme (2). In healthy subjects,

acetylation of platelet cyclooxygenase by oral aspirin is dose-dependent and cumulative with repeated drug administration (14).

The results of the present study demonstrate the dose dependence, cumulative nature, and selectivity of the inhibition by oral aspirin of TXB₂ production in whole blood clotting. This rather simple *ex vivo* model perhaps mimics the *in vivo* situation more closely than conventional studies carried out in platelet-rich plasma with the addition of exogenous stimuli (7, 10). During whole blood clotting thrombin is the major factor responsible for platelet aggregation and release, and the time course of its formation (15) is quite similar to that of TXB₂ in healthy subjects (7).

Our finding that a single 100-mg dose of aspirin causes a ceiling inhibitory effect on platelet TXB₂ production would suggest that currently used antithrombotic doses (16) are supramaximal with respect to the antiplatelet effect of the drug. One possible interpretation of the reportedly limited efficacy of aspirin, used as an antithrombotic agent, might be related to concomitant inhibition of platelet TXA₂ formation and vascular production of PGI₂, a vasodilator and inhibitor of platelet aggregation (3). As a consequence, numerous recent studies have addressed the question of how to dissociate platelet from vascular effects of the drug. Although Masotti et al. (17) found no inhibition of circulating PGI₂-like activity measured in healthy volunteers following single aspirin doses of 2 and 2.5 mg/kg (17), this finding has not been substantiated by other investigators studying *ex vivo* PGI₂ production by human venous biopsies (4, 18). One basic assumption underlying these studies is that PGI₂ is a physiologically important circulating antiplatelet hormone in man, as originally suggested by Gryglewski et al. (19) and Moncada et al. (20). However, the recent measurement of endogenous rate of secretion (21), peripheral plasma concentration and *t*_{1/2} (9, 22), and basal pulmonary formation of PGI₂ in healthy man (23) are consistent with a local rather than systemic nature of PGI₂ action.

The rationale of our approach was: (a) the repeated use of daily low-dose aspirin (as defined by the dose-effect relationship), causing greater percentage reduction of TXB₂ production than daily platelet turnover, should virtually abolish this modulatory pathway; (b) selectivity of this pharmacologic effect should be sought for in clinically relevant areas of cyclooxygenase activity i.e. in well defined targets of aspirin action. Our finding of cumulative inhibition of platelet TXB₂ production by daily low-dose aspirin is consistent with previous demonstration by Burch et al. (14) of cumulative acetylation of platelet cyclooxygenase by a daily dose of 20 mg. Greater than 95% reduction of platelet TXB₂ production could be maintained on a

long-term basis, during daily aspirin intake of 0.45 mg/kg in healthy subjects. However, since this effect is dependent upon platelet turnover as well as aspirin sensitivity of platelet and megakaryocyte cyclooxygenase, the adequacy of this therapeutic regimen might vary in different disease states. We suggest that this can be tested in each individual patient by the use of serum TXB₂ measurements before and during aspirin therapy with negligible blood loss, thus allowing the minimal effective dose of the drug to be established and periodically monitored.

Following cessation of chronic aspirin therapy, platelet TXB₂ production returned toward control values at a substantially similar rate as after a single dose of the drug (7). Thus, it would appear that this therapeutic regimen does not affect platelet turnover nor thrombin-induced activation of newly released platelets.

Previous investigators have suggested that the therapeutic benefit of aspirin as an antithrombotic agent is restricted to men (24, 25). In our study, we found no obvious difference in the extent, duration and selectivity of aspirin effects between healthy men and women.

Evidence was presented that a daily administration of aspirin 0.45 mg/kg for 1–4 wk does not reduce the urinary excretion of PGE₂, PGF_{2α}, and 6-keto-PGF_{1α}. Since these reflect, within limits, the renal synthesis of PGE₂, PGF_{2α} (11), and PGI₂ (9), respectively, these results suggest that medullary and/or cortical sites of cyclooxygenase are not inhibited by low-dose aspirin in healthy subjects. Since PGI₂ biosynthesis has been described in human renal medullary and cortical microsomes (26), it is not clear to what extent urinary 6-keto-PGF_{1α} reflects a vascular vs. nonvascular origin within the kidney. Although urinary collection periods <7 h were not investigated, because of lower reproducibility, it can not be excluded that low-dose aspirin might reversibly inhibit renal sites of cyclooxygenase by 20–30%. In fact, our results are compatible with either no inhibitory effect or with a partial inhibition only lasting 2–3 h following aspirin administration. However, the coefficients of variation of urinary PGE₂, PGF_{2α}, and 6-keto-PGF_{1α} excretion, measured during the control period, allow us to conclude that if such transient inhibition indeed occurred it was fully reversible and not cumulative. The finding of 40–60% reduction of urinary PGE₂, PGF_{2α}, and 6-keto-PGF_{1α} excretion following daily administration of a higher dose of aspirin in two of the same subjects indicates adequacy of the experimental conditions used to monitor aspirin effects on renal PG-synthesis. That renal PGI₂ formation was unaffected by chronic use of low-dose aspirin was further substantiated by the furosemide studies. We have recently demonstrated that fu-

roseamide-induced renin release is associated with increased renal PGI₂ formation and suggested that PGI₂ is a local modulator of juxtaglomerular function in man (9). The finding of a normal pattern of furosemide-induced increase of renin release and urinary 6-keto-PGF_{1α} excretion after 3–4 wk of aspirin treatment further indicates that renal PGI₂-producing cells are readily activable at a time of virtually complete suppression of platelet cyclooxygenase activity. Since acutely reduced renal PG-synthesis can adversely affect renal function in a number of disease states characterized by sodium depletion, hypotension or ineffective circulatory volume (27), one might anticipate a lower incidence of renal side-effects in these patients by the use of low-dose aspirin, as defined in the present study. The use of anti-platelet agents in nephrology (28) might represent a special case for testing this hypothesis.

Furthermore, by not interfering with furosemide-induced renal PGI₂ formation low-dose aspirin might have an additional advantage over high-dose aspirin in patients chronically treated with both drugs. Approximately 30% of patients recovered from myocardial infarction, studied by the Aspirin Myocardial Infarction Study Research Group, were reported to be on diuretics and possibly other drugs requiring intact vascular PG synthesis (29). The finding that low-dose aspirin does not affect renal PGI₂ synthesis does not necessarily imply a similar selectivity in other vascular districts. However, it provides a rationale for further studies in clinically relevant areas.

We conclude that in healthy subjects: (a) aspirin causes a dose-dependent (in the range 12 to 100 mg) inhibition of platelet TXA₂ production, with no obvious sex-related difference; (b) the inhibitory effect of low-dose (0.45 mg/kg per d) aspirin is cumulative upon repeated administration on platelet TXA₂ but not on renal PG synthesis; (c) during chronic low-dose aspirin therapy, renal PGI₂-producing cells are readily activable by furosemide, at a time of virtually complete suppression of platelet cyclooxygenase activity.

ACKNOWLEDGMENTS

We wish to thank Drs. P. Cattani, G. Ciabattini, P. Minuz, A. Pierucci, F. Pugliese, and M. A. Satta, the medical students and nurses of the Catholic University School of Medicine for their generous cooperation throughout the studies; Ms. Angelamaria Zampini for expert editorial assistance; Dr. J. E. Pike for several generous gifts of PG and TXB₂; Dr. M. J. Dunn and Dr. L. Caprino for a gift of anti-TXB₂ sera; Dr. J. Rokach for a gift of LTC₄ and LTD₄.

This study was supported by grants from Consiglio Nazionale delle Ricerche (80.00351.86 of Progetto Finalizzato Tecnologie Biomediche, Subprogetto CHIM-2, and 80.00545.04 and 81.00321.04 of Neuroendocrinopharmacology Research Unit UCSC).

REFERENCES

1. Patrignani, P., P. Cattani, P. Minuz, and C. Patrono. 1981. Low-dose aspirin: how low, how often? *Clin. Res.* **29**: 343A (Abstr.).
2. Roth, G. J., N. S. Stanford, and P. W. Majerus. 1975. Acetylation of prostaglandin synthetase by aspirin. *Proc. Natl. Acad. Sci. U.S.A.* **72**: 3073-3076.
3. Flower, R. J., S. Moncada, and J. R. Vane. 1980. Analgesic-antipyretics and anti-inflammatory agents. In *The Pharmacological Basis of Therapeutics*. A. Goodman Gilman, L. S. Goodman, and A. Gilman, editors. MacMillan Publishing Co., New York. 6th edition, 682-728.
4. Preston, F. E., S. Whipps, C. A. Jackson, A. J. French, P. J. Wyld, and C. J. Stoddard. 1981. Inhibition of prostacyclin and platelet thromboxane A_2 after low-dose aspirin. *N. Engl. J. Med.* **304**: 76-79.
5. Bianchi Porro, G., I. Caruso, G. Ciabattoni, P. Patrignani, C. Patrono, and F. Pugliese. 1981. Comparative effects of aspirin and diflunil on platelets and gastric prostaglandin-synthetase in humans. *Br. J. Pharmacol.* **72**: 141P-142P.
6. Plotz, P. H., and R. P. Kimberly. 1981. Acute effects of aspirin and acetaminophen on renal function. *Arch. Intern. Med.* **141**: 343-348.
7. Patrono, C., G. Ciabattoni, E. Pinca, F. Pugliese, G. Castrucci, A. De Salvo, M. A. Satta, and B. A. Peskar. 1980. Low dose aspirin and inhibition of thromboxane B_2 production in healthy subjects. *Thromb. Res.* **17**: 317-327.
8. Ciabattoni, G., F. Pugliese, G. A. Cinotti, G. Stirati, R. Ronci, G. Castrucci, A. Pierucci, and C. Patrono. 1979. Characterization of furosemide-induced activation of the renal prostaglandin system. *Eur. J. Pharmacol.* **60**: 181-187.
9. Patrono, C., F. Pugliese, G. Ciabattoni, P. Patrignani, A. Maseri, S. Chierchia, B. A. Peskar, G. A. Cinotti, B. M. Simonetti, and A. Pierucci. 1982. Evidence for a direct stimulatory effect of prostacyclin on renin release in man. *J. Clin. Invest.* **69**: 231-239.
10. Patrono, C., G. Ciabattoni, F. Pugliese, E. Pinca, G. Castrucci, A. De Salvo, M. A. Satta, and M. Parachini. 1980. Radioimmunoassay of serum thromboxane B_2 : a simple method of assessing pharmacologic effects on platelet function. *Adv. Prostaglandin Thromboxane Res.* **6**: 187-191.
11. Frölich, J. C., T. W. Wilson, B. J. Sweetman, M. Smigel, A. S. Nies, K. Carr, J. T. Watson, and J. A. Oates. 1975. Urinary prostaglandins. Identification and origin. *J. Clin. Invest.* **55**: 763-770.
12. Ciabattoni, G., F. Pugliese, M. Spaldi, G. A. Cinotti, and C. Patrono. 1979. Radioimmunoassay measurement of prostaglandins E_2 and $F_{2\alpha}$ in human urine. *J. Endocrinol. Invest.* **2**: 173-182.
13. Haber, E., T. Koerner, L. B. Page, B. Kliman, and A. Purnode. 1969. Application of a radioimmunoassay for angiotensin I to the physiologic measurement of plasma renin activity in normal human subjects. *J. Clin. Endocrinol.* **29**: 1349-1355.
14. Burch, J. W., N. Stanford, and P. W. Majerus. 1978. Inhibition of platelet prostaglandin synthetase by oral aspirin. *J. Clin. Invest.* **61**: 314-319.
15. Schuman, M. A., and S. P. Levine. 1980. Relationship between secretion of platelet factor 4 and thrombin generation during in vitro blood clotting. *J. Clin. Invest.* **65**: 307-313.
16. Passamani, E. R. 1980. Summary of ongoing clinical trials of platelet-active drugs in cardiovascular disease. *Circulation.* **62** (Suppl. V): 106-110.
17. Masotti, G., G. Galanti, L. Poggesi, R. Abbate, and G. G. Neri Serneri. 1979. Differential inhibition of prostacyclin production and platelet aggregation by aspirin. *Lancet.* **II**: 1213-1216.
18. Hanley, S. P., J. Bevan, S. R. Cockbill, and S. Heptinstall. 1981. Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. *Lancet.* **I**: 969-971.
19. Gryglewski, R. J., R. Korbut, and A. Oceletkiewicz. 1978. Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. *Nature (Lond.)*. **273**: 765-767.
20. Moncada, S., R. Korbut, S. Bunting, and J. R. Vane. 1978. Prostacyclin is a circulating hormone. *Nature (Lond.)*. **273**: 767-768.
21. FitzGerald, G. A., A. R. Brash, P. Falardeau, and J. A. Oates. 1981. Estimated rate of prostacyclin secretion into the circulation of normal man. *J. Clin. Invest.* **68**: 1272-1276.
22. Christ-Hazelhof, E., and D. H. Nugteren. 1981. Prostacyclin is not a circulating hormone. *Prostaglandins.* **22**: 739-746.
23. Edlund, A., W. Bomfim, L. Kaijser, C. Olin, C. Patrono, E. Pinca, and Å. Wennmalm. 1981. Pulmonary formation of prostacyclin in man. *Prostaglandins.* **22**: 323-332.
24. Harris, W. H., E. W. Salzman, C. A. Athanasoulis, A. C. Waltman, and R. W. De Sanctis. 1977. Aspirin prophylaxis of venous thromboembolism after total hip replacement. *N. Engl. J. Med.* **297**: 1246-1249.
25. The Canadian Cooperative Study Group. 1978. A randomized trial of aspirin and sulfipyrazone in threatened stroke. *N. Engl. J. Med.* **299**: 53-59.
26. Hassid, A., and M. J. Dunn. 1980. Microsomal prostaglandin biosynthesis of human kidney. *J. Biol. Chem.* **255**: 2472-2475.
27. Dunn, M. J., and E. J. Zambraski. 1980. Renal effects of drugs that inhibit prostaglandin synthesis. *Kidney Int.* **18**: 609-622.
28. Editorial. 1981. Anti-platelet agents in nephrology. *Lancet.* **I**: 426-427.
29. Aspirin Myocardial Infarction Study Research Group. 1980. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. *JAMA (J. Am. Med. Assoc.)*. **243**: 661-669.